Solventum (FRA:KB7) Stock Based Compensation: €140 Mil (TTM As of Mar. 2026)


FRA:KB7 Solventum Corp FRA:KB7
26 GF Score
Price €67.00
! 6 Warning Signs
View Full Analysis

What is Solventum Stock Based Compensation?

Solventum FRA:KB7 -0.30% 26 Stock Based Compensation is €140 Mil as of Mar. 2026. GuruFocus rates FRA:KB7 with a GF Score™ of 26/100. The stock has 6 warning signs investors should review.

Solventum's Stock Based Compensation for the three months ended in Mar. 2026 was €44 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was €140 Mil.

Solventum Stock Based Compensation Related Terms

Solventum Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Solventum's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solventum Stock Based Compensation Chart

Solventum Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial 33.63 34.93 35.76 106.96 137.49

Solventum Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 45.33 29.48 34.93 31.60 44.12
FRA:KB7
26GF Score
Solventum Corp FRA:KB7
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Solventum Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €140 Mil.

What does a Stock Based Compensation of €140 Mil mean?
Solventum (FRA:KB7) has a Stock Based Compensation of €140 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Solventum and its competitors.
Is Solventum's Stock Based Compensation too high?
Solventum's current Stock Based Compensation is €140 Mil. Overall, Solventum has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Solventum's Stock Based Compensation compare to COO and ALGN?
Solventum's Stock Based Compensation of €140 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Devices & Instruments company?
A good Stock Based Compensation depends on the Medical Devices & Instruments industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Solventum and its competitors. Solventum's current Stock Based Compensation is €140 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solventum stock overvalued right now?
Solventum (FRA:KB7) has a current Stock Based Compensation of €140 Mil. The current Stock Based Compensation is €140 Mil. Solventum's overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Solventum (FRA:KB7), the current Stock Based Compensation is €140 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Solventum Business Description

Address 2510 Conway Avenue East, 3M Center, Building 275-6W, Maplewood, MN, USA, 55144
Solventum Corp is a healthcare company developing, manufacturing, and commercializing solutions leveraging material science, data science, and digital capabilities to address customer and patient needs. Its segments include MedSurg, which earns maximum revenue and provides wound therapy, I.V. site management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and OEM medical technologies; Dental Solutions, offering dental and orthodontic products such as brackets, restorative cements, and bonding agents; and Health Information Systems, providing software solutions including physician documentation, coding automation, speech recognition, and data visualization platforms. It operates in the United States, which earns the majority of revenue, and internationally.
26GF Score

Get the complete analysis for FRA:KB7

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€67.00
Price